CDMO Selection Criteria: How Sponsors Actually Choose a CDMO, Reverse-Engineered for BD Teams
Most CDMO business development teams sell the way they wish sponsors bought: a capabilities deck, a site tour, a price. Sponsors do not buy that way. Behind every RFP there is a scorecard, formal or informal, and it ranks reliability and quality far above cost. If you know what is on that scorecard and how it is weighted, every one of your first three meetings can be built to score points on it. This article rebuilds the sponsor's CDMO selection criteria from the published survey data, then flips each criterion into what your BD team has to prove, and when.
Key Takeaways
Reliability outranks price: across ISR's outsourcer surveys, reliable on-time delivery and capacity to meet demand have become the top two decision drivers, while low cost, staff experience and regulatory filing support have all slipped in importance since 2020.
The biggest gap is the biggest opening: on-time delivery is the number one selection criterion, yet sponsors rank CDMOs' actual performance on it only 16th. A CDMO that can prove schedule adherence with data wins on the criterion competitors talk about but cannot evidence.
Tech transfer is now a selection criterion, not a post-contract detail: roughly 50 percent of tech transfers hit quality problems, and biologics transfers typically take 9 to 15 months rather than the 3 to 6 that pitch decks promise. Sponsors are scoring your transfer record before they sign.
Geography and ownership are on the 2026 scorecard: with the BIOSECURE Act signed into law in December 2025 and CDMO consolidation accelerating, sponsors are adding supply-chain origin, change-of-control terms and financial stability to their weighting.
Sequence your proof: meeting one is about modality fit and capacity, meeting two is about quality and compliance evidence, meeting three is about tech transfer, governance and commercial terms. Most CDMO BD teams front-load price and never get to meeting three.
Why the sponsor scorecard matters more in 2026
The CDMO market is large and still growing: estimates for 2026 cluster around 185 billion to 275 billion US dollars depending on scope, with consensus growth in the 6 to 10 percent CAGR range (GM Insights, Mordor Intelligence, Towards Healthcare). Roughly 87 percent of drug originators outsource at least one manufacturing activity, and small-molecule API outsourcing reached about 89 percent of FDA novel approvals in 2025. If you want the full market breakdown, see our CDMO market size 2026 analysis.
Demand is not the problem. Selection is. Nearly half of biopharma companies (49 percent in the most recent BioPlan survey cited by ISR) report difficulty finding a CDMO with available mammalian capacity, and at the same time sponsors are cutting vendor counts and shifting from project-level to enterprise-level partnerships. The result is a buyer who has more options than ever on paper, less patience than ever for risk, and a scorecard that has moved decisively away from price.
If you are still clarifying where a CDMO sits relative to a CRO in the sponsor's vendor map, start with our CRO vs CDMO guide.
The 7 CDMO selection criteria sponsors actually weigh
The weights below are Corstrate's synthesis of ISR's annual outsourcer surveys (2020 to 2025), IntuitionLabs' 2026 CDMO selection guide, and what we see in live RFP processes for our clients. Treat them as directional: every sponsor adjusts the weighting to the program, and a Phase 1 biotech weighs speed and flexibility more heavily than a commercial-stage pharma weighs them.
# | Selection criterion | Typical weight | Trend since 2020 | What the sponsor is really asking |
1 | Reliable on-time delivery and schedule adherence | 20% | Rising sharply | "Will you hit the dates you commit to, and can you prove it?" |
2 | Quality and regulatory inspection history (FDA, EMA, MHRA) | 20% | Stable, top tier | "Will you create a regulatory problem for my filing?" |
3 | Modality and technical fit | 15% | Stable | "Have you made something like this, at this scale, recently?" |
4 | Capacity and scalability (clinical to commercial) | 15% | Rising | "Will there be a slot when I need it, and will it survive your next acquisition?" |
5 | Tech transfer track record | 10% | Rising, new to top 10 | "How many transfers did you complete on time last year, and what went wrong on the ones that slipped?" |
6 | Geography, supply-chain origin and BIOSECURE exposure | 10% | New in 2024 to 2026 | "Where are your raw materials, your sites and your owners?" |
7 | Financial stability and ownership | 5% | Rising with M&A | "Will you still exist, under the same name and management, in three years?" |
8 | Price competitiveness (tie-breaker) | ~5% | Falling | "Are you within range?" (not "are you cheapest") |
Two things stand out. First, price does not disappear, but it has become a threshold rather than a driver: sponsors want a number within range, then decide on the other seven criteria. ISR's tracking shows "low cost" declining in importance over three consecutive survey years while capacity and on-time delivery rose. Second, three of the seven (tech transfer, geography, financial stability) barely existed as formal criteria five years ago. A BD narrative built in 2021 is missing 25 percent of the 2026 scorecard.
Criterion 1: reliable on-time delivery
This is where the market is most broken, and therefore where the biggest BD opportunity sits. ISR's analysis of sponsor feedback puts reliable on-time delivery first among selection drivers and only 16th among the attributes CDMOs actually deliver well. Contract Pharma's coverage of the capacity crunch tells the same story from the other side: CDMOs overcommit slots and underdeliver dates.
What BD must prove: schedule adherence as a number, not an adjective. "We delivered 91 percent of GMP batches within the committed window in 2025, and here is what happened on the 9 percent" is a sentence that wins RFPs. "We pride ourselves on reliability" is not.
Criterion 2: quality and inspection history
FDA enforcement has intensified. After a brief pause in early 2025, the agency issued 327 warning letters between July and early December 2025, a 73 percent increase on the same period in 2024 (Reed Smith, Scilife). Several went to CDMOs, including high-profile letters for contamination and data-integrity failures. Every sponsor procurement lead has read them.
What BD must prove: the last three regulatory inspections, with outcomes, and the CAPA record. If there was a 483, bring it to the meeting yourself with the closure evidence. Sponsors will find it anyway, and finding it first destroys trust in everything else you said.
Criterion 3: modality and technical fit
This is the criterion most CDMOs believe they lead with, and the one where they most often lose to a narrower specialist. Sponsors reward recent, relevant, at-scale experience over a broad capabilities list.
What BD must prove: two or three anonymized case studies that match the sponsor's modality, phase and scale, with the specific technical problem that was solved. A 35-slide capabilities deck signals that you do not know which of your capabilities matters to this buyer.
Criterion 4: capacity and scalability
Capacity is scarce in mammalian and advanced therapy manufacturing, and sponsors have learned that a slot promised by a CDMO that is about to be acquired may not exist after close. Outsourced Pharma's 2026 forecast notes that sponsors now write change-of-control provisions and capacity guarantees that survive ownership changes into contracts.
What BD must prove: a realistic slot window for this program, a clear path from clinical to commercial scale, and an honest answer on ownership stability. Offering a capacity reservation mechanism before the sponsor asks for one is a strong differentiator.
Criterion 5: tech transfer track record
Industry data presented at CDMO Live 2025 put the share of tech transfers with quality problems at around 50 percent. Realistic biologics transfer timelines run 9 to 15 months from kickoff to first released GMP batch, and commercial transfers often stretch to 12 to 18 months (CDMO World, IntuitionLabs). Sponsors who have been burned once now score transfer readiness as a formal criterion.
What BD must prove: the number of transfers completed in the last 24 months, median time to first GMP batch, and a named transfer lead the sponsor will actually work with. Bring the transfer lead to meeting three.
Criterion 6: geography and BIOSECURE exposure
The BIOSECURE Act was signed into law on 18 December 2025 as part of the FY2026 NDAA. Enforcement is not expected before late 2028, but a BIO survey of 124 biopharma companies found 79 percent had at least one agreement with a China-based or China-owned CDMO, and BIO estimates switching a partner can take up to eight years for advanced programs. Sponsors are therefore scoring supply-chain origin today, well ahead of the deadline. For the reshoring angle, see our BIOSECURE Act CDMO opportunity article.
What BD must prove: a one-page supply-chain origin map covering sites, critical raw materials, and ultimate ownership. US and EU CDMOs that produce this proactively turn a compliance question into a competitive advantage.
Criterion 7: financial stability and ownership
CDMO consolidation is accelerating, and sponsors increasingly monitor vendor M&A as part of risk management. A boutique CDMO can win on this criterion by being transparent: private ownership, no debt-driven sale process, management continuity.
What BD must prove: ownership structure and a credible three-year continuity story. Do not wait to be asked.
Flipping the scorecard: what to prove in the first three meetings
The mistake most CDMO BD teams make is not the content, it is the sequence. They lead with price and capabilities, which are the two least differentiating items on the scorecard, and never earn the third meeting where tech transfer, governance and terms are decided. The table below is the sequence we use with clients.
Meeting | Sponsor's unspoken question | Criteria being scored | What to bring | What not to bring |
Meeting 1 (discovery, 45 min) | "Are you even relevant to this program?" | Modality fit, capacity window | 2 to 3 matched case studies, a realistic slot window, questions about their process and timeline | The full capabilities deck, a price |
Meeting 2 (technical and quality, 60 to 90 min) | "Will you create a regulatory or delivery risk?" | Quality history, on-time delivery, geography | Last 3 inspection outcomes, batch schedule-adherence data, supply-chain origin map, QA lead in the room | Generic quality slogans, evasion on any 483 |
Meeting 3 (partnership and terms) | "Can we actually work together for five years?" | Tech transfer record, financial stability, price within range | Transfer metrics and the named transfer lead, ownership and continuity statement, indicative pricing with assumptions, proposed governance cadence | A price with no assumptions, a contract template the sponsor has not asked for |
If you run these three meetings well, your RFP response writes itself, because you already know which criteria the sponsor weights and which of your proof points landed. Our guide on how to respond to a CDMO or CRO RFP covers the written stage in detail.
How to build your own proof file
The seven criteria above are only useful to a BD team if the evidence exists in a form that can be shared in a meeting. In our experience, most mid-sized CDMOs have the data but have never assembled it. A practical proof file contains: (1) schedule-adherence statistics for the last eight quarters, (2) the last three regulatory inspection summaries with CAPA closure, (3) three to five anonymized case studies indexed by modality, phase and scale, (4) tech transfer metrics (count, median duration, root causes on delays), (5) a supply-chain origin map, (6) an ownership and continuity one-pager, and (7) a capacity window statement updated monthly.
Building this file is usually a two to four week project involving QA, operations and finance, and it is the single highest-return BD investment a CDMO can make, because it converts every meeting from a pitch into an evidence review. Once it exists, it also feeds your pipeline discipline: you can qualify out sponsors whose weighting you cannot win, which is the core of the approach we describe in our pipeline optimization guide.
Where boutique CDMOs win and lose on the scorecard
Large integrated CDMOs score well on capacity, geography (multiple sites) and financial stability. They score less well on on-time delivery (overcommitted slots), responsiveness and named-person continuity. Boutique and mid-sized CDMOs typically win on modality depth, schedule adherence for the programs they take, and transparency, and lose on capacity scalability and perceived financial risk.
The practical implication: do not try to out-score a mega-CDMO on breadth. Pick the three criteria you win on, lead every meeting with evidence on those three, and neutralize (not win) the others. This is the same logic behind the broader business development challenges for CDMOs we see across our client base.
Conclusion
Sponsors choose CDMOs on a scorecard where reliability, quality and fit carry roughly 55 percent of the weight, tech transfer, geography and ownership carry another 25 percent, and price is a tie-breaker. Understanding these CDMO selection criteria lets a BD team stop guessing and start sequencing: prove relevance in meeting one, prove low risk in meeting two, prove partnership capability in meeting three. The CDMOs that do this consistently are not the largest ones. They are the ones whose BD teams know what the buyer is scoring.
If you want help building your proof file or restructuring your first-three-meetings sequence, Corstrate works with CDMOs and CROs in the US and EU on exactly this.
Frequently asked questions
What are the most important CDMO selection criteria for sponsors in 2026? Reliable on-time delivery and quality/regulatory inspection history rank highest, followed by modality fit, capacity and scalability, tech transfer track record, geography and BIOSECURE exposure, and financial stability. Price has fallen to a tie-breaker role in most sponsor scorecards, according to ISR's outsourcer surveys and IntuitionLabs' 2026 selection guide.
How much does price matter when a sponsor chooses a CDMO? Less than most CDMO BD teams assume. ISR tracking shows "low cost" declining in importance over three consecutive survey years, while on-time delivery and capacity rose. Sponsors want a price within range, then decide on reliability, quality and fit.
Why is tech transfer now a CDMO selection criterion? Because it fails so often. Industry data presented at CDMO Live 2025 put the share of tech transfers with quality problems at about 50 percent, and biologics transfers typically take 9 to 15 months rather than the 3 to 6 that are often promised. Sponsors now score a CDMO's transfer record before contract signature.
How does the BIOSECURE Act affect CDMO selection? The Act became law in December 2025 with enforcement not expected before late 2028, but a BIO survey found 79 percent of biopharma companies had at least one agreement with a China-based or China-owned CDMO, and switching can take years. Sponsors are already scoring supply-chain origin and ownership as a selection criterion.
What should a CDMO BD team present in the first meeting with a sponsor? Two or three case studies matched to the sponsor's modality, phase and scale, a realistic capacity window, and questions about the sponsor's process and timeline. Not the full capabilities deck and not a price: those belong to later meetings, once fit and risk have been established.
Sources
ISR Reports, CDMO Performance on Service Provider Selection Criteria: https://isrreports.com/cdmo-performance-service-provider-selection-criteria/
ISR Reports, Tracking the Evolution of CDMO Selection Criteria: https://isrreports.com/tracking-evolution-cdmo-selection-criteria-biologic-drug-substance-manufacturing/
ISR Reports, How Industry Benchmarks Can Inform CDMO Selection: https://isrreports.com/how-industry-benchmarks-can-inform-cdmo-selection/
IntuitionLabs, CDMO Selection Guide: Due Diligence, Scorecards and KPIs (January 2026): https://intuitionlabs.ai/articles/cdmo-selection-guide
Outsourced Pharma, 2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For: https://www.outsourcedpharma.com/doc/2026-cdmo-forecast-the-shifts-sponsors-need-to-prepare-for-0001
Contract Pharma, The CDMO Capacity Crunch Persists: https://www.contractpharma.com/the-cdmo-capacity-crunch-persists/
Reed Smith, FDA inspections in 2025: https://www.reedsmith.com/articles/fda-inspections-in-2025-heightened-rigor-data-driven-targeting-and-increased-surveillance/
Scilife, FDA Warning Letters 2025: https://www.scilife.io/blog/worst-fda-warning-letters-pharma
CDMO World, How Long Does Biologics Tech Transfer Take: https://cdmoworld.com/how-long-does-biologics-tech-transfer-take-real-timeline/
IntuitionLabs, Pharma Tech Transfer Guide: https://intuitionlabs.ai/articles/pharma-tech-transfer-cdmo-guide
Hogan Lovells, BIOSECURE Act included in the FY2026 NDAA: https://www.hoganlovells.com/en/publications/biosecure-act-included-in-senate-version-of-the-2026-ndaa
Morrison Foerster, BIOSECURE Act Update (December 2025): https://www.mofo.com/resources/insights/251218-biosecure-act-update
GM Insights, Pharmaceutical CDMO Market Size 2026 to 2035: https://www.gminsights.com/industry-analysis/pharmaceutical-cdmo-market
Mordor Intelligence, Pharmaceutical CDMO Market: https://www.mordorintelligence.com/industry-reports/pharmaceutical-contract-development-and-manufacturing-organization-cdmo-market
Comments